AHR-1709

AHR-1709 is an experimental antipsychotic of the tryptamine family which was never marketed.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

AHR-1709 is an experimental antipsychotic of the tryptamine family which was never marketed. It is a cyclized tryptamine, more specifically an analogue of pip-tryptamine. AHR-1709 shows high affinity for the serotonin 5-HT 1A and 5-HT 2A receptors (K i = 27–44 nM and 4.8 nM, respectively) and for the dopamine D 2 receptor (K i = 81 nM).

It may act as a serotonin 5-HT 1A receptor antagonist. The drug also shows high affinity for ketanserin-labeled serotonin 5-HT 2A receptors (K i = 9.33–12.6 nM) and is a potent antagonist of these receptors (A 2 = 24.6–120 nM).

The drug produces antipsychotic-like effects in rodents, including reversal of hyperlocomotion but without induction of catalepsy, antagonism of stereotypy, or elevation of prolactin levels. AHR-1709 also produces antiemetic effects in rodents.

It is a derivative of the dopaminergic neurotoxin MPTP and is a weak dopamine reuptake inhibitor similarly but with 23-fold higher potency ( = 4,200 nM and 95,200 nM, respectively). However, unlike MPTP, AHR-1709 did not produce dopaminergic neurotoxicity in rodents.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378619088 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001378619088 · captured 2026-10-05 · ledger · version history

Cite this page as: encyclopegia.org, “AHR-1709”, snapshot enwiki-001378619088. https://encyclopegia.org/a/ahr-1709

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.